In this interview with The American Journal of Managed Care® (AJMC®), Igor Puzanov, MD, of Roswell Park Comprehensive Cancer Center and Jacobs School of Medicine and Biomedical Sciences, University of Buffalo, discusses the state of treatment selection in the setting of resected advanced melanoma, why sequencing of therapies does not occur in the setting of adjuvant therapy, and best practices to keep in mind for patient education and managing their treatment-related toxicities.
2022
SWOG S1801: Neoadjuvant and Adjuvant Pembrolizumab for Patients With Stage IIIB to IV Melanoma
Patients with high-risk melanoma who received the anti–PD-1 therapy pembrolizumab both before and after surgery to remove cancerous tissue had a significantly lower risk of their cancer recurring than similar patients who received the drug only after surgery.
Researchers discover potential new melanoma treatment, giving hope to patients
HMRI and University of Newcastle researchers have discovered that treating patients who have late-stage treatment resistant melanoma with a combination of two existing drugs significantly increases their survival times.
Antibiotics make melanoma worse by depleting gut microbiome, finds study
The use of far-ranging antibiotics in mice with malignant melanoma, a severe type of skin cancer, increased their metastatic bone growth. This is likely because the drugs lessened the intestinal flora in mice and weakened the immune response, finds a new study by researchers at Emory University